Shenwan Hongyuan Group (06806) has completed the issuance of 2 billion yuan perpetual subordinated bonds.
Shenwan Hongyuan (06806) announced that, in accordance with the China Securities Regulatory Commission's "Approval on the Public Issuance of Perpetual Subordinated Bonds by Shenwan Hongyuan Securities Co., Ltd. to Professional Investors" (CSRC Permit [2026] No. 1645), the company's subsidiary, Shenwan Hongyuan Securities Co., Ltd., has been approved to publicly issue perpetual subordinated bonds with a total face value of no more than 30 billion yuan.
Shenwan Hongyuan Group (06806) announced that, according to the approval from the China Securities Regulatory Commission regarding the public issuance of perpetual subordinated bonds by Shenwan Hongyuan Group Securities Co., Ltd. to professional investors (Zheng Jian Xu Ke [2026] No. 1645), the company's subsidiary, Shenwan Hongyuan Group Securities Co., Ltd., has been authorized to publicly issue perpetual subordinated bonds with a total face value not exceeding 30 billion yuan.
The issuance of the second phase of perpetual subordinated bonds (hereinafter referred to as "the bonds") by Shenwan Hongyuan Group Securities Co., Ltd. to professional investors concluded on September 7, 2026. The issuance scale of these bonds is 2 billion yuan, with a coupon rate of 1.89%. The bonds will be issued with a floating interest rate, calculated annually on a simple interest basis without compounding, maintaining the same rate during the first five interest periods, and resetting every five years starting from the sixth interest period. Each five-year period will serve as one repricing cycle, at the end of which the issuer has the right to either extend the bond term by one repricing cycle (thus extending it for another five years) or redeem the bonds in full. Following the completion of registration for the bonds, they are expected to be listed and traded on the Shenzhen Stock Exchange.
Related Articles

BOAN BIOTECH (06955) spent HKD 2.922 million on September 9 to repurchase 1 million shares.

DINGDANG HEALTH (09886) invested HK$336,300 to repurchase 420,000 shares on September 9.

Shanghai Supezet Engineering Technology Corp., Ltd. (688121.SH): Preliminary investigation reveals that some annual financial information is suspected of false recording, which may involve circumstances of significant legal violations leading to mandatory delisting.
BOAN BIOTECH (06955) spent HKD 2.922 million on September 9 to repurchase 1 million shares.

DINGDANG HEALTH (09886) invested HK$336,300 to repurchase 420,000 shares on September 9.

Shanghai Supezet Engineering Technology Corp., Ltd. (688121.SH): Preliminary investigation reveals that some annual financial information is suspected of false recording, which may involve circumstances of significant legal violations leading to mandatory delisting.

RECOMMEND





